Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia"

Haematologica

Volumn 98, Issue 12, 2013, Pages

  Palmi, Chiara ^a   Lana, Tobia ^b   Silvestri, Daniela ^a   Savino, Angela ^a   Kronnie, Geertruy Te ^b   Conter, Valentino ^a   Basso, Giuseppe ^b   Biondi, Andrea ^a   Valsecchi, Maria Grazia ^a   Cazzaniga, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Copy number abnormalities; IKZF1 deletions; Pediatric Ph BCP ALL; Prognosis

Indexed keywords

IKAROS TRANSCRIPTION FACTOR; IKZF1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CHROMOSOMAL INSTABILITY; GENE DELETION; GENE EXPRESSION; HUMAN; LETTER; MORBIDITY; OUTCOME ASSESSMENT; PHILADELPHIA 1 CHROMOSOME; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION;

COPY NUMBER ABNORMALITIES; IKZF1 DELETIONS; PEDIATRIC PH- BCP-ALL; PROGNOSIS;

FEMALE; GENE DELETION; GENETIC MARKERS; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84889820389     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.099077     Document Type: Letter

References (9)

1. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lym- phoblastic leukemia? Haematologica. 2013;98(8):1226-31.
2. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et al. IKZF1 deletion is associated with a poor outcome in pediatric B- cell precursor acute lymphoblastic leukemia in Japan. Cancer Med. 2013;2(3):412-9.
3. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98(4):597-601.
4. Brady BL, Steinel NC, Bassing CH. Antigen receptor allelic exclusion: an update and reappraisal. J Immunol. 2010;185(7):3801-8.
5. Mullighan CG, Su X, Zhang J, Radtke I, Philips LAA, Miller CB, et al. Deletion of IKZF1 and Prognois in Aute Lymphoblastic Leukemia. N Engl J Med. 2009;360(5):470-80.
6. Mullighan CG, Miller CB, Radtke I, Phillips LA, Ma J, White D, et al. BCR-ABL1 lymphoblastic leukemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-4.
7. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome- wide classification study. Lancet Oncol. 2009;10(2):125-34.
8. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874-84.
9. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012;26(10):2245-53.